ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

VIY Vialogy

0.205
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Vialogy VIY London Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.205 00:00:00
Open Price Low Price High Price Close Price Previous Close
0.205
more quote information »

Vialogy VIY Dividends History

No dividends issued between 28 Mar 2014 and 28 Mar 2024

Top Dividend Posts

Top Posts
Posted at 28/6/2014 14:32 by jsbach123
I claim no superior knowledge though it is clear to me from your posting that you have not followed VIY for long. To answer your question Gekko I lost a few hundred pounds on the buses more than four years ago and have not held since but have continued to follow the company having done the research as to why I believed the spin and I comment upon it to correct the blatant ramping and misinformation that sometimes is posted.

However concerning VIY soon to be reincarnated going from a digital tech snake oil product to a medical diagnostic product still remains very high risk IMHO and if diagnostics was proven would IMHO have been snapped up. Medical/research communities are small and knowledge is shared widely and quickly among their members.
Posted at 15/6/2014 14:24 by spec7
VIY no longer exists, no doubt a new thread will be formed once the GM passes the new company that reversed into the old VIY therefore this thread is now closed.
Posted at 14/6/2014 22:00 by alimo
"..don't rain on my parade!" eh? CAUTION - Who is funding Premaitha right now and paying all the R&D and big salaries they must have been incurring. I wonder how long it takes to start the negotiations and agree a price, then complete all the paperwork and come up with an RTO presentation to our shareholders. I know AR has been sold on the benefits of IONA by what seems to be a strong team at Premaitha and he knows we are a willing audience of hopeful PIs that want our investment in VIY to recover. It all seems to be pretty, but is it? AR seems to be able to come along and deal off the top of the pack a company that has the midas technology that will come into production in 2015. Ten plus years ago we heard of a company called VIY that had a midas product in QRI/QRD - is this the same story repeating itself, or has AR really got our shareholders interests at heart. He seems to be in right now but for how long once he pulls off this deal and made his cash he steps out and leaves. How much do we know about IONA(R), and the competition from probably many other biotechs. Surely if IONA does work then why haven't one of the big bios like AZN snapped it up already. I've heard some talk about risk/reward. Has all the R&D been completed, or are we being asked to give our £1.3m to fund the marketing of a product that may or may not be accepted by that market because of the other competion? Take a look at this, sound familiar?
hxxp://www.fool.com/investing/general/2014/05/02/why-sequenom-inc-shares-took-flight.aspx and


hxxp://www.sequenom.com/

Sound pretty similar and what is the difference between what they have and what we are being sold, and how do our patents differ from theirs? hmm...
Posted at 14/6/2014 19:46 by multibagger
Bioprojects -> Original Investments -> Vialogy -> Premaitha....been there and got the well worn tee shirt over 11+ years ! I suppose it is a fresh start with new personalities and very little more to lose.

Biotech space is really hot at the moment with more to come over the coming years and I have trying to see what the link is between Premaitha and Illumina is (Illumina was recently voted the smartest company in the world by MIT Technology Review ahead of Tesla, Google(came third) etc and I have a lot of time for MIT TR as they know their stuff).

Having lost more than most on VIY...I'm gonna watch and see where this goes. I already have significant exposure to Biotech through AXA Framlington Biotech anyway, so not in a hurry. Already hold decent numbers of Tissue Regenix (TRX) & Summit Corp (SUMM).

Premaitha looks good on paper with a sound management (technical and commercial) team, who have actually created share holder value and IONA being a product that does not need development of new lab infrastructure,addresses a felt need in a big and growing market and potentially Premaitha business model adaptable to other products in development.....

Cautiously optimistic after having written off £178k in VIY....

Good luck all :)
Posted at 13/6/2014 12:18 by the prophet
Spec7
-we've still got our share of VEC, but its unlikely to be worth much/anything, as SG can't seem to get funding for it.

What a lot of posters who are banging on about bond/quantumRD/the past don't seem to realise is this is now a new company with a new bod. VIY failed, and this is a second bite. Premaitha has nothing to do with VIY, other than VIY is being used as a shell for the AIM listing.

I am very happy with the current situation.
Posted at 13/6/2014 06:55 by jack shit
VIY used to be a Biotech stock before becoming VIY in 2006.

They were Bioprojects Int.(BIP) in 2002 before a reverse take-over to become VIY in 2006.

lol.
Posted at 03/6/2014 08:30 by dj trading
Agreed Spec - my valuation is much lower

Let's not forget that an acquired business has owners and they will want to max valuation. Given current and past performance of VEC I don't think much if any value will be attributed to this part of the business so essentially VIY have cash and an AIM listing although perhaps the biggest asset is the shareholder base - but I won't comment on why!!!

I value VIY at cash plus an unknown value for investor hope.

My current estimate of cash is circa £1.2m equivalent to 0.045p/share

The value of the listing might round this to 0.05p

The big unknown is the value of investor hope that Adam can wave his wand or that somebody will buy VEC and whilst this might double or more the cash valuation - I don't think it will hold the price above 0.1p in the longer term. Short term who knows how excited investors will get - might even go up for a month or two or perhaps longer!!

And with the current price just under 0.2p I accept that Mr Market values VEC, Adam and hope at 3* cash and a lot more than me, but then I'm an accountant and I can't value hope but I do recognise it exists!!!

So in summary I think the deal (the important bit) will be done at 0.05p £1.35m valuation of VIY but the share price might end up significantly higher than this.

Anyway as TP says we shall soon see - all speculation until then. Good to observe and learn for future reference though.

Dave
Posted at 09/5/2014 12:27 by the prophet
Nothing to do with VIY , other than AR is common to both DUC and VIY.Expect news on the VIY front soon.
Posted at 27/1/2014 20:43 by dj trading
TP
Re oversubscription and Deano/Sandeep minimal investment.

Deano and Sandeep know more than anyone about VIY and in particular VEC prospects and funding progress. The 0.1p placing values VEC (via 75% VIY holding at) at just $5.23m (see below) assuming VIY cash has zero value which clearly it hasn't. If Deano and Sandeep thought VEC was going to get funding at a valuation of $20m for VEC they would surely have loaded up for a 3 bagger and it would have made potential investors take note. They can surely afford given salary take for the past 7 years!

As for oversubscription by PIs - completely meaningless as nobody has a clue what is going on with VEC and circa 70% of the current £4m valuation is attributable to VEC. I personally can't see how Adam can turn £1.2m into £4m especially in facilities! - just doesn't stack up for me

Re Director investments - As I have previously said, Adam perhaps invested to "oil the wheels" on the placing/offer but I am completely at a loss to understand why the new non exec would make such a significant investment. Either a ray of hope or lack of due diligence!?

My VEC valuation in post 10354
"VEC valuation - well new placees at 0.1p will own 41% of VIY equivalent to 31% of VEC based on 75% shareholding by VIY. So having paid £1.1m for 31% of VEC even assuming zero value for VIY cash they have valued VEC at a maximum of £1.1/.31 or £3.2m or just $5.23m
Posted at 17/1/2014 12:33 by dj trading
I see the usual suspects are getting excited about a 20% rise over the past few days - forgetting about the 93% fall over the past 12 months.

Of course I was wrong to mention cash, placings and capital reorganisation last year - and got told so every time I did!

Anyway - as for now
VEC valuation - well new placees at 0.1p will own 41% of VIY equivalent to 31% of VEC based on 75% shareholding by VIY. So having paid £1.1m for 31% of VEC even assuming zero value for VIY they have valued VEC at a maximum of £1.1/.31 or £3.2m or just $5.23m

How are VEC going to raise money at a valuation of $20m when UK placees have valued at max $5.2m and that assumes VIY has zero value.
On that basis VEC won't get the necessary funding and IP will return to UK - or more likely terms will be varied - either way little value to VIY.

VIY raising circa £1.6m perhaps £1.4m after expenses but they have been running on fumes for a couple of months and will have a number of creditors knocking at the door. Notably legal and advisor fees, salaries and expenses and general admin costs leaving perhaps £1.25m in the pot or about 0.05p/share cash.

The one thing that does confuse me is Nick Mustoe's significant investment. It is not unusual for Exec Directors to take part in placings to "oil the wheels" but for a new non exec to invest so much is unusual - so perhaps a ray of hope!

GL - Dave

Your Recent History

Delayed Upgrade Clock